Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Itron (ITRI) Research & Development (2016 - 2025)

Itron's Research & Development history spans 17 years, with the latest figure at $53.1 million for Q4 2025.

  • For Q4 2025, Research & Development fell 8.97% year-over-year to $53.1 million; the TTM value through Dec 2025 reached $103.8 million, down 51.75%, while the annual FY2025 figure was $207.0 million, 3.72% down from the prior year.
  • Research & Development reached $53.1 million in Q4 2025 per ITRI's latest filing, up from $12.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $58.3 million in Q4 2024 to a low of $12.3 million in Q3 2025.
  • Average Research & Development over 5 years is $45.5 million, with a median of $49.7 million recorded in 2021.
  • Peak YoY movement for Research & Development: increased 18.88% in 2023, then crashed 76.51% in 2025.
  • A 5-year view of Research & Development shows it stood at $49.9 million in 2021, then dropped by 6.48% to $46.6 million in 2022, then grew by 15.64% to $53.9 million in 2023, then grew by 8.2% to $58.3 million in 2024, then fell by 8.97% to $53.1 million in 2025.
  • Per Business Quant, the three most recent readings for ITRI's Research & Development are $53.1 million (Q4 2025), $12.3 million (Q3 2025), and $12.5 million (Q2 2025).